Form 4: Nuvalent CLO exercises options, sells 5,500 shares

Chief Legal Officer Deborah Ann Miller exercised options and sold 5,500 Nuvalent shares on March 26, 2026 under a Rule 10b5-1 plan.

Summary

• On March 26, 2026, Chief Legal Officer Deborah Ann Miller exercised 5,500 stock options at an exercise price of $6.89 (Code M) and sold 5,500 Class A shares in three transactions the same day (Code S).
• Weighted average sale prices were $97.50 (range: $96.89–$97.85) for 940 shares, $98.21 (range: $97.92–$98.85) for 1,757 shares, and $99.46 (range: $99.09–$99.80) for 2,803 shares.
• Post-transaction direct ownership: 59,634 Class A shares; derivatives remaining: 83,608 stock options.
• Transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on November 18, 2024; the option exercised is fully vested and carries an expiration date of April 29, 2031.
• The filing was signed on March 30, 2026 by an attorney-in-fact.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as neutral: a routine, pre-planned option exercise and matched sale with no net change to direct share count and no implications for operating performance.

Positives

• Trades executed under a pre-established Rule 10b5-1 plan adopted on November 18, 2024, supporting orderly, compliant insider transactions.
• Direct holdings remain at 59,634 shares after the transactions, with 83,608 stock options still beneficially owned.
• Sales matched the number of shares acquired via option exercise (5,500), implying no net change in direct share count versus pre-transaction.
• The exercised options are fully vested, reducing uncertainty around future vesting events.

Negatives

• Insider sold 5,500 shares on March 26, 2026 at weighted average prices between approximately $97 and $100.
• Insider selling activity, even under a 10b5-1 plan, can be perceived cautiously by some investors.

Future Outlook

No forward-looking statements or company guidance are provided; this is a routine insider transaction executed under a pre-established Rule 10b5-1 plan.

Management Comments

• Transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on November 18, 2024.
• Reported prices are weighted averages; full trade-by-trade details within the stated ranges are available upon request.
• The shares underlying the exercised option are fully vested.

Industry Context

StockSavvy.ai notes that pre-planned 10b5-1 insider trades are common across biotech and broader life sciences, often resulting in neutral signaling since sales are scheduled and frequently coincide with option exercises for liquidity or tax purposes.

Comparison to Industry Standards

• Use of a Rule 10b5-1 plan aligns with best-practice governance seen at peers in biotech and pharma (e.g., Vertex, Alnylam, Moderna), where executives routinely pre-schedule trades.
• Selling only the number of shares acquired via option exercise is consistent with industry norms for cashless or tax-related exercises, and typically has limited information content about fundamentals.

Stakeholder Impact

• Shareholders: Insider sale under a Rule 10b5-1 plan; direct share count unchanged versus pre-transaction as sales matched the exercised shares.
• Regulatory/compliance: Clear adherence to Rule 10b5-1 and Section 16 reporting, with weighted-average price disclosures and ranges.
• Insiders/employees: Demonstrates use of fully vested options and liquidity via same-day exercise and sale.

Key Dates

Recommendation

The pre-planned nature of the trades, sales equal to exercised shares, and unchanged direct holdings suggest a routine liquidity event with limited signaling value for fundamentals; no change to investment stance based solely on this filing.

Keywords

Nuvalent, NUVL, Form 4, insider transaction, insider sale, Rule 10b5-1, stock option exercise, beneficial ownership, biotech, Cambridge